## CITATION REPORT List of articles citing

Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts

DOI: 10.1371/journal.pmed.1001764 PLoS Medicine, 2014, 11, e1001764.

Source: https://exaly.com/paper-pdf/57870452/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
223	Lung Cancer Screening With Low-Dose CT in the United States. <b>2015</b> , 12, 1395-402		21
222	Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?. <b>2015</b> , 10, 1285-1291		20
221	Prediction of risk of lung cancer in populations and in pulmonary nodules: Significant progress to drive changes in paradigms. <b>2015</b> , 89, 1-3		18
220	Bringing Access to the Full Spectrum of Cancer Research: A Call for Papers. <i>PLoS Medicine</i> , <b>2015</b> , 12, e <sup>2</sup>	001861	<b>7</b> <sub>7</sub> 8
219	Correction: Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001787	11.6	
218	The 10 Pillars of Lung Cancer Screening: Rationale and Logistics of a Lung Cancer Screening Program. <b>2015</b> , 35, 1893-908		63
217	Searching for red shirts. Emphysema as a lung cancer screening criterion?. <b>2015</b> , 191, 868-9		1
216	CongrE de lEssociation amEicaine de recherche contre le cancer l'AACR 2015. <b>2015</b> , 17, 277-298		
215	Lung Cancer Screening. <b>2015</b> , 95, 967-78		14
214	Estimating eligibility for lung cancer screening in an Australian cohort, including the effect of spirometry. <b>2016</b> , 204, 406		4
213	Region specific lung nodule management practice guideline. <b>2016</b> , 8, 2319-2323		3
212	Just Say No! Smoking Abstinence Works. <b>2016</b> , 193, 476-7		
211	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <b>2016</b> , 64, 720-31		9
210	Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. <b>2016</b> , 122, 1150-9		71
209	Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines. <b>2016</b> , 3, e000166		17
208	Predicting Malignant Nodules from Screening CTs. <b>2016</b> , 11, 2045-2047		12
207	Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. <b>2016</b> , 315, 2300-11		151

206	Lung cancer screening: latest developments and unanswered questions. <b>2016</b> , 4, 749-761	51
205	[Lung cancer screening - risk stratification : Who should undergo screening?]. <b>2016</b> , 56, 798-802	
204	What is the Optimum Screening Strategy for the Early Detection of Lung Cancer. <b>2016</b> , 28, 672-681	9
203	Lung Cancer Screening Update. <b>2016</b> , 31, 190-200	8
202	Lung cancer screening - practical challenges of confining participation to those who might benefit. <b>2016</b> , 40, 205-6	5
201	Lung cancer screening makes the GRADE. <b>2016</b> , 89, 315-316	
200	Trends in Subpopulations at High Risk for Lung Cancer. <b>2016</b> , 11, 194-202	23
199	Proportion of Non-Small-Cell Lung Cancer Patients that Would Have Been Eligible for Lung Cancer Screening. <b>2016</b> , 17, e131-e139	6
198	CT screening for lung cancer: Is the evidence strong enough?. <b>2016</b> , 91, 29-35	31
	Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent	
197	low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. <b>2016</b> , 17, 590-9	108
197		164
	diagnostic screening trial. <b>2016</b> , 17, 590-9	
196	diagnostic screening trial. <b>2016</b> , 17, 590-9  Scientific Advances in Lung Cancer 2015. <b>2016</b> , 11, 613-638	164
196	diagnostic screening trial. 2016, 17, 590-9  Scientific Advances in Lung Cancer 2015. 2016, 11, 613-638  Lung cancer screening: did we really need a randomized controlled trial?. 2016, 50, 29-33  Lung cancer screening: utility of molecular applications in conjunction with low-dose computed	164 3
196 195 194	diagnostic screening trial. 2016, 17, 590-9  Scientific Advances in Lung Cancer 2015. 2016, 11, 613-638  Lung cancer screening: did we really need a randomized controlled trial?. 2016, 50, 29-33  Lung cancer screening: utility of molecular applications in conjunction with low-dose computed tomography guidelines. 2016, 16, 435-47  Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed	164 3 13
196 195 194 193	Scientific Advances in Lung Cancer 2015. 2016, 11, 613-638  Lung cancer screening: did we really need a randomized controlled trial?. 2016, 50, 29-33  Lung cancer screening: utility of molecular applications in conjunction with low-dose computed tomography guidelines. 2016, 16, 435-47  Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. 2016, 14, 409-418	164 3 13 36
196 195 194 193	Scientific Advances in Lung Cancer 2015. 2016, 11, 613-638  Lung cancer screening: did we really need a randomized controlled trial?. 2016, 50, 29-33  Lung cancer screening: utility of molecular applications in conjunction with low-dose computed tomography guidelines. 2016, 16, 435-47  Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. 2016, 14, 409-418  Screening for Lung Cancer. Improving Outcomes with Better Patient Selection. 2016, 193, 478-9	164 3 13 36 5

188	Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study. <b>2017</b> , 35, 861-869	50
187	Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?. <b>2017</b> , 35, 818-819	2
186	Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. <b>2017</b> , 72, 389-400	28
185	Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations. <b>2017</b> , 17, 191	13
184	Chronic Obstructive Pulmonary Disease as a Lung Cancer Risk: Worth Its Weight in "GOLD". <b>2017</b> , 14, 309-310	1
183	Optimum low dose CT screening interval for lung cancer: the answer from NELSON?. <b>2017</b> , 72, 6-7	6
182	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <b>2017</b> , 12, 1210-1222	73
181	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <b>2017</b> , 195, 1150-1160	57
180	Lung Cancer Screening. <b>2017</b> , 101, 769-785	52
179	Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study. <b>2017</b> , 141, 94-101	13
178	Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. <b>2017</b> , 196, e15-e29	57
177	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. <b>2017</b> , 18, 1523-1531	93
176	Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening. <b>2017</b> , 12, 1646-1653	9
175	Progress and prospects of early detection in lung cancer. <b>2017</b> , 7,	282
174	Canadian Association of Radiologists: Guide on Computed Tomography Screening for Lung Cancer. <b>2017</b> , 68, 334-341	1
173	A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells. <b>2017</b> , 17, 301	2
172	A consensus statement on the gender perspective in lung cancer. <b>2017</b> , 19, 527-535	16
171	Applying Risk Prediction Models to Optimize Lung Cancer Screening: Current Knowledge, Challenges, and Future Directions. <b>2017</b> , 4, 307-320	7

## (2018-2017)

170	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002277	129
169	Risk Stratification for Second Primary Lung Cancer. <b>2017</b> , 35, 2893-2899	50
168	Demographic, psychosocial, and behavioral associations with cancer screening among a homeless population. <b>2018</b> , 35, 281-290	7
167	Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. <b>2018</b> , 16, 412-441	248
166	Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. <b>2018</b> , 153, 954-985	147
165	Computed Tomography Scanning for Early Detection of Lung Cancer. <b>2018</b> , 69, 235-245	4
164	Deteccifi sistemfica del cficer de pulmfi. <b>2018</b> , 22, 1-7	
163	Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps. <b>2018</b> , 91, 20170460	9
162	Screening for Lung Cancer. <b>2018</b> , 52-58.e3	1
161	Healthy Patients at Risk for Lung Cancer. <b>2018</b> , 197-208	1
160	Challenges in Lung Cancer Screening in Latin America. <b>2018</b> , 4, 1-10	7
159	Selecting lung cancer screenees using risk prediction models-where do we go from here. <b>2018</b> , 7, 243-253	20
158	Editorial on PanCan study. <b>2018</b> , 7, S57-S59	
157	The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants. <b>2018</b> , 7, 336-346	10
156	Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs. <b>2018</b> , 7, 254-271	15
155	Screening for early stage lung cancer and its correlation with lung nodule detection. <b>2018</b> , 10, S846-S859	10
154	Cancer pulmonaire : dpistage, biomarqueurs et immunit[]2018, 10, 129-134	
153	Low rates of eligibility for lung cancer screening in patients undergoing computed tomography coronary angiography. <b>2018</b> , 48, 1265-1268	1

152	Identifying Patients for Whom Lung Cancer Screening Is Preference-Sensitive: A Microsimulation Study. <b>2018</b> , 169, 1-9	37
151	Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. <b>2018</b> , 110, 1201-1207	48
150	Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening. <b>2018</b> , 169, 10-19	75
149	Chronic obstructive pulmonary disease (COPD) and lung cancer screening. <b>2018</b> , 7, 347-360	25
148	Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria. <b>2018</b> , 13, e0195441	4
147	Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening. <b>2018</b> , 289, 218-224	12
146	Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. <b>2018</b> , 198, e3-e13	32
145	Current and Former Smokers: Who Wants To Be Screened?. <b>2018</b> , 19, 493-501	6
144	Yield of Low-Dose Computerized Tomography Screening for Lung Cancer in High-Risk Workers: The Case of 7189 US Nuclear Weapons Workers. <b>2018</b> , 108, 1296-1302	9
143	Lung cancer screening. <b>2018</b> , 237-255	1
143	Lung cancer screening. 2018, 237-255  Improving Implementation of Lung Cancer Screening With Risk Prediction Models. 2018, 169, 54-55	1 2
142	Improving Implementation of Lung Cancer Screening With Risk Prediction Models. <b>2018</b> , 169, 54-55	2
142	Improving Implementation of Lung Cancer Screening With Risk Prediction Models. <b>2018</b> , 169, 54-55  Risk-Targeted Lung Cancer Screening. <b>2018</b> , 169, 199-200  POINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet	2
142 141 140	Improving Implementation of Lung Cancer Screening With Risk Prediction Models. 2018, 169, 54-55  Risk-Targeted Lung Cancer Screening. 2018, 169, 199-200  POINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? Yes. 2018, 153, 1299-1302  COUNTERPOINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? No. 2018,	2 2 5
142 141 140	Improving Implementation of Lung Cancer Screening With Risk Prediction Models. 2018, 169, 54-55  Risk-Targeted Lung Cancer Screening. 2018, 169, 199-200  POINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? Yes. 2018, 153, 1299-1302  COUNTERPOINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? No. 2018, 153, 1303-1305  The potential impact of chronic obstructive pulmonary disease in lung cancer screening:	2 2 5
142 141 140 139	Improving Implementation of Lung Cancer Screening With Risk Prediction Models. 2018, 169, 54-55  Risk-Targeted Lung Cancer Screening. 2018, 169, 199-200  POINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? Yes. 2018, 153, 1299-1302  COUNTERPOINT: Should Lung Cancer Screening Be Expanded to Persons Who Don't Currently Meet Accepted Criteria Set Forth by the CHEST Guidelines on Lung Cancer Screening? No. 2018, 153, 1303-1305  The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic. 2019, 13, 699-707  Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of	2 2 5 2

134	Lung Cancer Screening: Use of Low-Dose Computed Tomography. <b>2019</b> , 55, 526-531	1
133	The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening. <b>2019</b> , 54,	4
132	Estimation of lung cancer risk using homology-based emphysema quantification in patients with lung nodules. <b>2019</b> , 14, e0210720	5
131	Impact of Tobacco Dependence in Risk Prediction Models for Lung Cancer Diagnoses and Deaths. <b>2019</b> , 3, pkz014	2
130	Update on screening for lung cancer. <b>2019</b> , 8, S77-S87	17
129	CT screening for lung cancer: Are we ready to implement in Europe?. <b>2019</b> , 134, 25-33	12
128	Implementation planning for lung cancer screening in China. <b>2019</b> , 2, 13-44	17
127	Second primary lung cancer in United States Cancer Survivors, 1992-2008. <b>2019</b> , 30, 465-475	13
126	The Patient Perspective on Lung Cancer Screening and Health Disparities. 2019, 16, 601-606	22
125	Lung Cancer Screening in Never-Smokers. <b>2019</b> , 14, 336-337	5
124	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. <b>2019</b> , 2, e190204	35
123	Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States. <b>2019</b> , 171, 384-386	14
122	Using Risk Models to Make Lung Cancer Screening Decisions: Evidence-Based and Getting Better. <b>2019</b> , 171, 669-670	6
121	Response to Dr. R⊞'s comment letter. <b>2019</b> , 8, 198-199	
120	Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy. <b>2019</b> , 8, S454-S459	8
119	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. <b>2020</b> , 29, 452-459	7
118	Cancer Progress and Priorities: Lung Cancer. <b>2019</b> , 28, 1563-1579	109
117	A blueprint for cancer screening and early detection: Advancing screening's contribution to cancer control. <b>2019</b> , 69, 50-79	47

116	Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids. <b>2019</b> , 16, 512-514	4
115	Development and evaluation of a consumer information resource, including Patient Decision Aid, for lung cancer screening: a quasi-experimental study. <b>2020</b> , 10, 404-412	2
114	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. <b>2020</b> , 112, 466-479	32
113	Screening and Early Detection. <b>2020</b> , 375-398.e7	1
112	The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers. <b>2021</b> , 15, 2544-2564	4
111	Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model. <b>2020</b> , 173, 704-713	18
110	Lung cancer screening in never-smokers: facts and remaining issues. <b>2020</b> , 56,	3
109	Improving identification of candidates for lung cancer screening in a high risk population. <b>2020</b> , 148, 79-85	1
108	The impact of perceived risk, screening eligibility and worry on preference for lung cancer screening: a cross-sectional survey. <b>2020</b> , 6,	3
107	Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document. <b>2020</b> , 4, 236-265	1
106	Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. <b>2020</b> , 10, e037075	14
105	Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model. <b>2020</b> , 8, E585-E592	7
104	Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. <b>2020</b> , 8, 709-716	38
103	Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities. <b>2020</b> , 15, 1738-1747	21
102	Lung cancer mortality among construction workers: implications for early detection. <b>2020</b> , 77, 207-213	6
101	Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data. <b>2020</b> , 35, 899-912	10
100	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. <b>2020</b> , 12,	18
99	Analysis of lung cancer risk model (PLCO and LLP) performance in a community-based lung cancer screening programme. <b>2020</b> , 75, 661-668	13

98	Risk-Based lung cancer screening: A systematic review. <b>2020</b> , 147, 154-186	28
97	Protocol and Rationale for the International Lung Screening Trial. <b>2020</b> , 17, 503-512	20
96	Disparities in Lung Cancer Screening: A Review. <b>2020</b> , 17, 399-405	30
95	Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population. <b>2020</b> , 9, 3983-3994	7
94	Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment. <b>2020</b> , 23, 495-505	3
93	Chronic non-communicable disease risk calculators - An overview, part I. <b>2021</b> , 143, 25-35	
92	Effects of Random Measurement Error on Lung Cancer Screening Decisions: A Retrospective Cohort-Based Microsimulation Study. <b>2021</b> , 159, 853-861	2
91	Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. <b>2021</b> , 58, 217-226	3
90	Lung Cancer Screening. <b>2021</b> , 161-177	
89	Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model. <b>2021</b> , 81, 1607-1615	6
88	A Comparative Performance Analysis of Data Resampling Methods on Imbalance Medical Data. <b>2021</b> , 9, 109960-109975	17
87	Pulmonary nodule radiological diagnostic algorithm in lung cancer screening. <b>2021</b> , 10, 1124-1135	2
86	Implementation of lung cancer screening: what are the main issues?. <b>2021</b> , 10, 1050-1063	5
85	Incorporating both genetic and tobacco smoking data to identify high-risk smokers for lung cancer screening. <b>2021</b> , 42, 874-879	5
84	Guideline-Discordant Lung Cancer Screening: Emerging Demand and Provided Indications. <b>2021</b> , 18, 395-405	1
83	Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges. <b>2021</b> , 149, 250-263	9
82	Comorbidity Profiles and Lung Cancer Screening among Older Adults: U.S. Behavioral Risk Factor Surveillance System 2017-2019. <b>2021</b> , 18, 1886-1893	2
81	Racial and socioeconomic disparities in lung cancer screening in the United States: A systematic review. <b>2021</b> , 71, 299-314	11

80	Lung cancer screening: who pays? Who receives? The European perspectives. 2021, 10, 2395-2406	3
79	Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users. <b>2021</b> , 25, 1-234	1
78	Do the 2013 United States Preventive Services Task Force guidelines for lung cancer screening fail high-risk African American smokers? An institutional retrospective observational cohort study. <b>2021</b> , 30, 375-381	О
77	Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT. <b>2021</b> , 30, 1472-1479	2
76	The impact of income and education on lung cancer screening utilization, eligibility, and outcomes: a narrative review of socioeconomic disparities in lung cancer screening. <b>2021</b> , 13, 3745-3757	4
75	Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience. <b>2021</b> , 156, 31-40	4
74	Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria. <b>2021</b> ,	3
73	Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. <b>2021</b> , 160, e427-e494	14
72	Contemporary issues in the implementation of lung cancer screening. 2021, 30,	3
71	Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer. 2021,	O
70	6-Year Risk of Developing Lung Cancer in Spain: Analysis by Autonomous Communities. 2020,	2
69	Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. <b>2021</b> , 4, e2120633	4
68	6-Year Risk of Developing Lung Cancer in Spain: Analysis by Autonomous Communities. <b>2021</b> , 57, 521-527	
67	Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report. <b>2021</b> ,	3
66	"PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma". <b>2021</b> , 51, 458-473	2
65	Lung cancer in Asian women and health system implications for Australia. <b>2017</b> , 18, 1570-1571	5
64	Disparities of National Lung Cancer Screening Guidelines in the US Population. 2020, 112, 1136-1142	23
63	Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD. <b>2020</b> , 75, 655-660	8

62	Do Lung Cancer Eligibility Criteria Align with Risk among Blacks and Hispanics?. 2015, 10, e0143789	26
61	Identifying Lung Cancer Risk Factors in the Elderly Using Deep Neural Networks: Quantitative Analysis of Web-Based Survey Data. <b>2020</b> , 22, e17695	8
60	Lung Cancer Screening with Low-Dose CT: Current Status in Other Countries. 2019, 80, 849	2
59	Risk Prediction Model for Lung Cancer Screening. <b>2019</b> , 80, 860	1
58	Lung cancer screening: identifying the high risk cohort. <b>2015</b> , 7, S156-62	18
57	Lung Cancer Screening with Low-Dose CT in Female Never Smokers: Retrospective Cohort Study with Long-term National Data Follow-up. <b>2018</b> , 50, 748-756	7
56	Lung Cancer: Genetics. 1-6	
55	Improving CT screening for lung cancer with a highly predictive risk model. <b>2018</b> , 6, 128	1
54	Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. <b>2019</b> , 24, 48-53	
53	Lung Cancer Screening: Use of Low-Dose Computed Tomography. <b>2019</b> , 55, 526-531	1
52	Screening. 12-23	
51	Risk-based prediction model for selecting eligible population for lung cancer screening among ever smokers in Korea <b>2021</b> , 10, 4390-4402	O
50	A risk prediction model for selecting high-risk population for computed tomography lung cancer screening in China. <b>2021</b> , 163, 27-34	2
49	USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study <b>2022</b> , 23, 138-148	5
48	Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China <b>2021</b> , 11, 766939	O
47	Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment <b>2022</b> , JCO2101460	1
46	Development, validation, and evaluation of prediction models to identify individuals at high risk of lung cancer for screening in the English primary care population using the QResearch database: research protocol and statistical analysis plan.	О
45	Identifying best modelling practices for tobacco control policy simulations: a systematic review and a novel quality assessment framework <b>2022</b> ,	O

44	Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility <b>2022</b> ,	3
43	The additional value of lung cancer screening program in identifying unrecognized diseases <b>2022</b> , 22, 48	O
42	Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention. <b>2022</b>	О
41	Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data <b>2022</b> ,	2
40	The Future of Lung Cancer Screening: Current Challenges and Research Priorities 2022, 14, 637-645	2
39	Lung Cancer Screening in Asbestos-Exposed Populations <b>2022</b> , 19,	1
38	Lung cancer incidence among world trade center rescue and recovery workers 2022,	
37	Prevalence, symptom burden and under-diagnosis of chronic obstructive pulmonary disease in Polish lung cancer screening population: a cohort observational study <b>2022</b> , 12, e055007	
36	Efficacy of Risk Prediction Models and Thresholds to Select Patients for Lung Cancer Screening <b>2022</b> , 8465371221089899	
35	Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study <b>2022</b> , 22, 165	
34	Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening. <b>2022</b> ,	0
33	Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines versus Risk-Based Criteria: The Multiethnic Cohort Study.	1
32	Potential Overdiagnosis with CT Lung Cancer Screening in Taiwanese Female: Status in South Korea. <b>2022</b> , 23, 571	1
31	Asian Lung Cancer Absolute Risk Models for lung cancer mortality based on China Kadoorie Biobank.	
30	Low-dose computed tomography screening, follow-up, and management of lung nodules DAn expert consensus statement from Taiwan. <b>2022</b> , 55, 94	
29	Predicting the future risk of lung cancer: development and validation of QCancer2 (10-year risk) lung model and evaluating the model performance of nine prediction models.	
28	Evaluation and Management of Indeterminate Pulmonary Nodules on Chest Computed Tomography in Asymptomatic Subjects: The Principles of Nodule Guidelines.	
27	Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial. 2200483	O

Lung Cancer Screening Criteria and Cardiopulmonary Comorbidities. 2022, 100377

25	Telephone risk-based eligibility assessment for low-dose CT lung cancer screening. thoraxjnl-2021-218634	О
24	Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry. 2200795	2
23	A Risk-Stratifieed Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in China.	Ο
22	Expanding the Reach of Lung Cancer Screening: Risk Models for Individuals Who Never Smoked.	
21	Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography.	
20	Best Practices in Lung Cancer Screening. <b>2022</b> , 27-55	0
19	Recalibrating risk prediction models by synthesizing data sources: adapting the lung cancer PLCO model for Taiwan.	O
18	Lung Cancer Absolute Risk Models for Mortality in Asian Population using China Kadoorie Biobank.	O
17	Implementation of an Integrated Lung Cancer Prevention and Screening Program Using a Mobile Computed Tomography (CT) Unit in Brazil. <b>2022</b> , 29, 107327482211213	1
16	Comparison of discrimination performance of 11 lung cancer risk models for predicting lung cancer in a prospective cohort of screening-age adults from Germany followed over 17 years. <b>2022</b> ,	O
15	Lung Cancer Screening in Never Smokers: CounterpointCannot Identify Which Never Smokers Are at Sufficient Risk to Balance the Potential Harms of Screening.	O
14	Eligibility to lung cancer screening among staffs of a university hospital: a large cross-sectional survey. <b>2022</b> , 100970	O
13	Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. <b>2022</b> , 14,	1
12	Lung Cancer Risk Prediction Nomogram in Nonsmoking Chinese Women: Retrospective Cross-sectional Cohort Study. 9, e41640	О
11	Toward More Effective Lung Cancer Risk Stratification to Empower Screening Programs for the Asian Nonsmoking Population. <b>2023</b> ,	Ο
10	Why Are Women More Likely to Be Overdiagnosed With Lung Cancer?. <b>2023</b> , 163, 22-24	О
9	Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.	Ο

8 Lung cancer screening in advanced chronic obstructive pulmonary disease: helpful or harmful?. thorax-2022-219778

7	OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations. <b>2023</b> , 88, 104443	1
6	The Intersection of Lung Cancer Screening, Radiomics, and Artificial Intelligence: Can One Scan Really Predict the Future Development of Lung Cancer?. <b>2023</b> , 41, 2141-2143	О
5	Risk Model <b>B</b> ased Lung Cancer Screening. <b>2023</b> , 176, 320-332	1
4	Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis. <b>2023</b> ,	О
3	Machine Learning System for Lung Neoplasms Distinguished Based on Scleral Data. <b>2023</b> , 13, 648	O
2	Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19[67 million people and evaluation of model performance against seven other risk prediction models. 2023,	0
1	Evaluation of the accuracy of the PLCOm20126-year lung cancer risk prediction model among smokers in the CARTaGENE population-based cohort. <b>2023</b> , 11, E314-E322	O